3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Melphalan
5
Dexamethasone
4
Bortezomib
3
Arsenic Trioxide
3
fludarabine phosphate
2
Vorinostat
2
Stem Cell Transplantation
2
Peripheral Blood Stem Cell Transplantation
2
Lenalidomide
2
Drug Therapy
2
Busulfan
2
Ascorbic Acid
2
ogalvibart
1
ethanolamine oleate
1
daratumumab
1
crexavibart
1
carfilzomib
1
Zoledronic Acid
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Therapeutics
1
Thalidomide
1
Tacrolimus
1
Surveys and Questionnaires
1
Sulfamethoxazole
1
Sodium Chloride
1
Simvastatin
1
Saline Solution, Hypertonic
1
Saline Solution
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms, Plasma Cell
×
crexavibart
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn